# US 5,346,989 A · Peptides for use in induction of T cell activation against HIV-1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,346,989 A
- Document ID: US5346989A
- Status: Granted
- Kind: A
- Application number: 08/121,032
- Filed: 1993-09-13
- Granted: 1994-09-13
- Earliest claimed: 1990-08-22
- Assignees: Syntello Vaccine Development KB
- Inventors: Anders Vahlne; Bo Svennerholm; Lars Rymo; Stig Jeansson; Peter Horal; Cecil Czerkinsky; Jan Holmgren
- Web page: https://patentgrep.com/patent/US5346989A

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61L 27/34: Macromolecular materials
- C07K 5/06165: {and Pro-amino acid; Derivatives thereof}
- C07K 5/0806: {the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala}
- C07K 5/1019: {with the first amino acid being basic}
- C07K 14/005: from viruses
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Peptides corresponding to regions of the human immunodeficiency virus protein gp-120 are provided for eliciting T-cell activation.

## Claims

### Claim 1

A peptide having the amino acid sequence X-Ser-Ser-Ser-Gly-Arg-Met-Ile-Met-Glu-Lys-Gly-Glu-Ile-Lys-Asn-Cys-Ser -Phe-Asn-Ile-Ser-Thr-Ser-Y wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by an amino group and a Cysteine residue followed by a hydroxy group.

### Claim 2

A peptide having the amino acid sequence X-Gly-Glu-Ile-Lys-Asn-Cys-Ser-Phe-Asn-Ile-Ser-Thr-Ser-Ile-Arg-Gly-Lys -Val-Gln-Lys-Glu-Tyr-Ala-Phe-Phe-Y wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by an amino group and a Cysteine residue followed by a hydroxy group.

### Claim 3

A peptide having the amino acid sequence X-Ile-Arg-Gly-Lys-Val-Gln-Lys-Glu-Tyr-Ala-Phe-Phe-Tyr-Lys-Leu-Asp-Ile -Ile-Pro-Ile-Asp-Asn-Asp-Thr-Thr-Ser-Tyr-Thr-Y wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by an amino group and a Cysteine residue followed by a hydroxy group.

### Claim 4

A peptide having the amino acid sequence X-Pro-Lys-Val-Ser-Phe-Glu-Pro-Ile-Pro-Ile-His-Tyr-Cys-Ala-Pro-Ala-Gly -Phe-Ala-Ile-Leu-Lys-Cys-Asn-Asn-Y wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by an amino group and a Cysteine residue followed by a hydroxy group.

### Claim 5

A peptide having the amino acid sequence X-Cys-Gly-Gly-Glu-Phe-Phe-Tyr-Cys-Asn-Ser-Thr-Gln-Leu-Phe-Asn-Ser-Thr -Trp-Phe-Asn-Ser-Thr-Trp-Y wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by an amino group and a Cysteine residue followed by a hydroxy group.

### Claim 6

A composition for the activation of T cells against human immunodeficiency virus comprising:
(a) an amount of a peptide sufficient to elicit T cell activation, the peptide having the amino acid sequence:
X-Ser-Ser-Ser-Gly-Arg-Met-Ile-Met-Glu-Lys-Gly-Glu-Ile-Lys-Asn-Cys -Ser-Phe-Asn-Ile-Ser-Thr-Ser-Y,
wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by an amino group and a Cysteine residue followed by a hydroxy group; and
(b) a physiologically acceptable carrier therefor.

### Claim 7

A composition for the activation of T cells against human immunodeficiency virus comprising:
(a) an amount of a peptide sufficient to elicit T cell activation, the peptide having the amino acid sequence:
X-Gly-Glu-Ile-Lys-Asn-Cys-Ser-Phe-Asn-Ile-Ser-Thr-Ser-Ile-Arg-Gly -Lys-Val-Gln-Lys-Glu-Tyr-Ala-Phe-Phe-Y,
wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by an amino group and a Cysteine residue followed by a hydroxy group; and
(b) a physiologically acceptable carrier therefor.

### Claim 8

A composition for the activation of T cells against human immunodeficiency virus comprising:
(a) an amount of a peptide sufficient to elicit T cell activation, the peptide having the amino acid sequence:
X-Ile-Arg-Gly-Lys-Val-Gln-Lys-Glu-Tyr-Ala-Phe-Phe-Tyr-Lys-Leu-Asp -Ile-Ile-Pro-Ile-Asp-Asn-Asp-Thr-Thr-Ser-Tyr-Thr-Y,
wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by an amino group and a Cysteine residue followed by a hydroxy group; and
(b) a physiologically acceptable carrier therefor.

### Claim 9

A composition for the induction of IL-2 production comprising:
(a) an amount of a peptide sufficient to elicit IL-2 production, the peptide having the amino acid sequence:
X-Pro-Lys-Val-Ser-Phe-Glu-Pro-Ile-Pro-Ile-His-Tyr-Cys-Ala-Pro-Ala -Gly-Phe-Ala-Ile-Leu-Lys-Cys-Asn-Asn-Y,
wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by a hydroxy group; and
(b) a physiologically acceptable carrier therefor.

### Claim 10

A composition for the activation of T cells against human immunodeficiency virus comprising:
(a) an amount of a peptide sufficient to elicit T cell activation, the peptide having the amino acid sequence:
X-Cys-Gly-Gly-Glu-Phe-Phe-Tyr-Cys-Asn-Ser-Thr-Gln-Leu-Phe-Asn-Ser -Thr-Trp-Phe-Asn-Ser-Thr-Trp-Y,
wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by an amino group and a Cysteine residue followed by a hydroxy group; and
(b) a physiologically acceptable carrier therefor.

### Claim 11

A composition for the activation of T cells against human immunodeficiency virus comprising:
(a) an amount of at least two peptides sufficient to elicit T cell activation, wherein the peptides are selected from the amino acid sequences: ##STR2## wherein X is either a hydrogen atom of the amino terminal NH.sub.2 group of said peptide or an additional amino acid selected to facilitate coupling of said peptide to a carrier and Y is selected from the group consisting of an amino group, a hydroxy group, a Cysteine residue, a Cysteine residue followed by an amino group and a Cysteine residue followed by a hydroxy group; and
(b) a physiologically acceptable carrier therefor.